Survival and response deepening after autologous transplantation in patients with multiple myeloma in Chile

Figures & data

Figure 1. Schemes of chemoimmunotherapy prior to autologous transplant. V = Bortezomib. R = Lenalidomide. T = Thalidomide. D = Dexamethasone. PACE = Cisplatin/doxorubicin/cyclophosphamide/etoposide.

Table 1. Characteristics of patients undergoing autologous stem cell transplantation (ASCT).

Patient characteristics	(n = 50)
Age (median, range)	58 (42-71)
Sex (masculine, percentage)	66%
Clinical manifestations (percentage)
a) Bone disease	86%
b) Anemia	44%
c) Hypercalcemia	20%
d) Renal injury	10%
Monoclonal component (percentage)
IgA Kappa	14%
Iga Lambda	8%
IgG Kappa	28%
IgG Lambda	20%
Kappa	14%
Lambda	12%
Non secretory	4%
ISS risk score (percentage)
I	46%
II	24%
III	30%
Performance status (percentage)
0	84%
1	12%
2	4%
3–4	0%
Induction chemotherapy (percentage/median cycles)
VCD	64%/4
VRD	12%/5
VCD/VRD sequential	8%/4-4
VTD	4%/5
CTD	4%/6
VTD-PACE	4%/2
RD	2%/8
VD	2%/4
Radiotherapy (percentage)	34%
Conditioning regimen (percentage)
Melphalan 200 mg/m^2	82%
Melphalan 140 mg/m^2	18%

ISS = International staging system. V = Bortezomib. R = Lenalidomide. T = Thalidomide. D = Dexamethasone. PACE = Cisplatin/doxorubicin/cyclophosphamide/etoposide.

Figure 2. Response criteria for patients with multiple myeloma before and after autologous transplant. VGPR: very good partial response. sCR: strict complete response. PD: disease progression. AutoHSCT: autologous hematopoietic stem cell transplantation.

Figure 3. Progression-free survival and overall survival in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Figure 4. Progression-free survival in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant according to pre-transplant (A), post-transplant response criteria (B–C) and measurable residual disease post-transplant (D).

Table 2. Adverse events reported in patients undergoing autologous transplant.

Adverse event	Type	Number	Percentage	Grade CCTAEC 5.0
Infections	Febrile neutropenia	14	28%	3
	Catheter related sepsis	1	2%	3
	Pseudomonas aeruginosa	1	2%	3
Gastrointestinal	Diarrhea	39	78%	2
Immunologic	Cutaneous rash secondary to antibiotic	2	4%	2
Transfusional	Febrile non hemolytic transfusion reaction	1	2%	1
	Cytokine release syndrome (related to infusion of hematopoietic progenitors)	1	2%	2
Graft related	Delayed engraftment	1	2%	3
	Engraftment syndrome	1	2%	2
Hemorrhage	Hematuria	1	2%	2
Circulatory	Distributive shock	1	2%	3
Psychiatric	Anxiety disorder	2	4%	2
	Delirium	1	2%	2